Ascendis Pharma A/S - Common Stock (ASND)

CUSIP: 04351P101

Q1 2022 13F Holders as of 31 Mar 2022

Holder snapshot 7 signals
Share change
+3,592,875
Put/Call ratio
66%
SEC-reported price per share
$117.36
Number of holders
169
Value change
+$416,027,513
Number of buys
88
Open additional details 1 more signal available
Number of sells
78
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
62,915,156

Security key

04351P101

Report period

Q1 2022

Institutions

169

Top holders

10

Ownership snapshot

Top reported holders of ASND - Ascendis Pharma A/S - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Artisan Partners Limited ...
Disclosed value leader
Artisan Partners Limited ...
Comparable rows
0/15
Latest evidence
31 Dec 2021
13F Highest disclosed value: $1,068,227,000 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Artisan Partners Limited Partnership has the largest disclosed position value at $1.07B.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Artisan Partners Limited Partnership's linked filing trail.
Disclosed position value Top 5
Artisan Partners Limited Partnership $1.07B
RA CAPITAL MANAGEMENT, L.P. $1.02B
FMR LLC $720.54M
PRICE T ROWE ASSOCIATES INC /MD/ $640.52M
BAKER BROS. ADVISORS LP $610.98M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Artisan Partners Limited Partnership
13F
Company
13F
—
denominator unverified
$1,068,227,000
7,940,434 shares
— 31 Dec 2021
RA CAPITAL MANAGEMENT, L.P.
13F
Company
13F
—
denominator unverified
$1,018,110,000
7,567,900 shares
— 31 Dec 2021
FMR LLC
13F
Company
13F
—
denominator unverified
$720,536,000
5,355,943 shares
— 31 Dec 2021
PRICE T ROWE ASSOCIATES INC /MD/
13F
Company
13F
—
denominator unverified
$640,523,000
4,761,193 shares
— 31 Dec 2021
BAKER BROS. ADVISORS LP
13F
Company
13F
—
denominator unverified
$610,982,000
4,541,604 shares
— 31 Dec 2021
WELLINGTON MANAGEMENT GROUP LLP
13F
Company
13F
—
denominator unverified
$547,635,000
4,070,724 shares
— 31 Dec 2021
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2022

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
169
Shares
61,928,932
Rows available
169
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2022 vs Q1 2022 Across Filers

Q1 2022 holders
169
Q1 2022 holders
169
Holder diff
0
Investor Q1 2022 Shares Q1 2022 Shares Share Diff Share Chg % Q1 2022 value Q1 2022 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .